<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240875</url>
  </required_header>
  <id_info>
    <org_study_id>EBL01</org_study_id>
    <secondary_id>2014-003518-10</secondary_id>
    <nct_id>NCT02240875</nct_id>
  </id_info>
  <brief_title>A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo</brief_title>
  <official_title>A Phase Ia, Dose-Escalating, Safety and Immunogenicity Trial of the Monovalent Zaire Ebola Viral Vector Candidate Vaccine cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen cAd3-EBO Z and MVA-BN® Filo in Healthy UK Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different
      doses, and a second vaccine, MVA-BN® Filo, at 3 different doses. The study will enable us to
      assess the safety of the vaccines and the extent of the immune response in healthy
      volunteers. The investigators will do this by giving volunteers a either one or two
      vaccinations, doing blood and saliva tests and collecting information about any symptoms that
      occur after vaccination. This is the first trial to use either of these vaccines in humans.
      We plan to recruit a total of 92 volunteers to be vaccinated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long- term immunology follow-up: In order to assess the durability of vaccine induced
      immunogenicity, all vaccinated subjects will be invited back to attend a maximum of 3 further
      optional follow up visits at least 12 months after their final vaccination. The 3 visits will
      have a minimum interval of 3 months between them, and the final visit must take place no
      longer than 12 months after the first optional visit.

      Volunteers who attend these visits will be asked about occurrence of any SAEs during the
      intervening period. SAE data for this period will not be collected in those volunteers who
      decline to attend these additional visits.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 17, 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of the Ebola Zaire vaccine cAd3-EBO Z when administered to healthy volunteers at 3 doses</measure>
    <time_frame>6 months</time_frame>
    <description>The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular and humoral immunogenicity of the Ebola Zaire vaccine cAd3-EBO Z when administered to healthy volunteers at 3 doses</measure>
    <time_frame>6 months</time_frame>
    <description>The primary immunogenicity outcome measures are ELISA and neutralization antigen-specific assays for antibody responses and intracellular cytokine staining (ICS) assay for T cell responses.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Ebola</condition>
  <condition>Ebola Zaire</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cAd3-EBO Z at 1 x 10^10 vp</intervention_name>
    <description>Low dose cAd3-EBO Z</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 1c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cAd3-EBO Z at 2.5 x 10^10 vp</intervention_name>
    <description>Medium dose cAd3-EBO Z</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 2c</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cAd3-EBO Z at 5 x 10^10 vp</intervention_name>
    <description>High dose cAd3-EBO Z</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 3b</arm_group_label>
    <arm_group_label>Group 3c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4.4x10^8 TCID50s MVA-BN® Filo</intervention_name>
    <description>High dose MVA-BN® Filo</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.2x10^8 TCID50s MVA-BN® Filo</intervention_name>
    <description>Low dose MVA-BN® Filo</description>
    <arm_group_label>Group 1c</arm_group_label>
    <arm_group_label>Group 2c</arm_group_label>
    <arm_group_label>Group 3c</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4.4 x 10^7 TCID50s MVA-BN® Filo</intervention_name>
    <description>Very low dose MVA-BN® Filo</description>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 18 to 50 years

          -  Able and willing (in the Investigator's opinion) to comply with all study requirements

          -  Willing to allow the investigators to discuss the volunteer's medical history with
             their general practitioner (GP)

          -  For females only, willingness to practice continuous effective contraception during
             the study and a negative pregnancy test on the day(s) of screening and vaccination

          -  Agreement to refrain from blood donation during the course of the study

          -  Provide written informed consent

        Exclusion Criteria:

          -  Participation in another research study involving receipt of an investigational
             product in the 30 days preceding enrolment, or planned use during the study period

          -  Prior receipt of an investigational Ebola or Marburg vaccine, a chimpanzee adenovirus
             vectored vaccine or any other investigational vaccine likely to impact on
             interpretation of the trial data

          -  Receipt of any live, attenuated vaccine within 28 days prior to enrolment

          -  Receipt of any subunit or killed vaccine within 14 days prior to enrolment

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the planned administration of the vaccine candidate

          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)
             immunosuppressant medication within the past 6 months (inhaled and topical steroids
             are allowed)

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine, (e.g. egg products) including urticaria, respiratory difficulty or
             abdominal pain

          -  Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.

          -  Any history of anaphylaxis in reaction to vaccination

          -  Pregnancy, lactation or willingness/intention to become pregnant during the study

          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in
             situ)

          -  History of serious psychiatric condition

          -  Poorly controlled asthma or thyroid disease

          -  Seizure in the past 3 years or treatment for seizure disorder in the past 3 years

          -  Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior
             history of significant bleeding or bruising following intramuscular injections or
             venepuncture

          -  Any other serious chronic illness requiring hospital specialist supervision

          -  Current anti-tuberculosis prophylaxis or therapy

          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater
             than 42 units every week

          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment

          -  Seropositive for hepatitis B surface antigen (HBsAg)

          -  Seropositive for hepatitis C virus (antibodies to HCV)

          -  Travel to a Ebola or Marburg endemic region during the study period or within the
             previous six months

          -  Any clinically significant abnormal finding on screening biochemistry or haematology
             blood tests or urinalysis (see Appendix A and Appendix B)

          -  Any other significant disease, disorder or finding which may significantly increase
             the risk to the volunteer because of participation in the study, affect the ability of
             the volunteer to participate in the study or impair interpretation of the study data

          -  Inability of the study team to contact the volunteer's GP to confirm medical history
             and safety to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian V S Hill</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola</keyword>
  <keyword>Zaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

